多分子形突出了与非小细胞肺癌免疫化疗耐药性相关的因素
Yilv Yan1, Dongqing Sun2,3, Junjie Hu1
1Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Nature genetics
|December 10, 2024
概括
非小细胞肺癌 (NSCLC) 免疫检查点阻塞 (ICB) 抵抗与瘤细胞和巨细胞的原沉积有关,阻碍T细胞的进入. 激活的三级淋巴体结构 (TLSs) 改善了结果,而缺氧会使预后恶化.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
背景情况:
- 免疫检查点封锁 (ICB) 已经彻底改变了非小细胞肺癌 (NSCLC) 治疗.
- 然而,很大一部分患者表现出对ICB疗法的耐药性.
- 了解瘤微环境 (TME) 是克服抗性的关键.
研究的目的:
- 在NSCLC TME中描述瘤细胞状态和空间细胞组成.
- 识别导致ICB抗性和响应能力的因素.
- 为个性化免疫化疗策略提供见解.
主要方法:
- 来自232080个细胞的单细胞转录组的分析.
- 来自19名NSCLC患者的空间分辨转录组的分析.
- 在ICB化疗前后评估TME细胞组成.
主要成果:
- 瘤细胞和SPP1+巨细胞与COL11A1+纤维细胞相互作用,促进原沉积,阻碍T细胞透.
- 在TME中确定了三级淋巴体结构 (TLS) 的不同状态.
- 激活的TLS与改善的预后相关,而低氧的TME抑制了TLS的发展,并与预后不佳有关.
结论:
- 特定的细胞相互作用和瘤边界的原纠有助于NSCLC中的ICB抵抗.
- TLS的状态和缺氧的存在是患者预后的关键决定因素.
- 这些发现为提高ICB在NSCLC中的疗效提供了新的目标.
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K